US20020012906A1 - Method for kidney disease treatment by drug intervention - Google Patents

Method for kidney disease treatment by drug intervention Download PDF

Info

Publication number
US20020012906A1
US20020012906A1 US09/893,346 US89334601A US2002012906A1 US 20020012906 A1 US20020012906 A1 US 20020012906A1 US 89334601 A US89334601 A US 89334601A US 2002012906 A1 US2002012906 A1 US 2002012906A1
Authority
US
United States
Prior art keywords
disease
albumin
protein
sample
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/893,346
Other languages
English (en)
Inventor
Wayne Comper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP7843A external-priority patent/AUPP784398A0/en
Application filed by Individual filed Critical Individual
Priority to US09/893,346 priority Critical patent/US20020012906A1/en
Assigned to MONASH UNIVERSITY reassignment MONASH UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COMPER, WAYNE D.
Publication of US20020012906A1 publication Critical patent/US20020012906A1/en
Priority to US10/721,351 priority patent/US20040106155A1/en
Assigned to NORTHSHORE ASSET MANAGEMENT, LLC reassignment NORTHSHORE ASSET MANAGEMENT, LLC SECURITY AGREEMENT Assignors: AUSAM BIOTECHNOLOGIES, INC.
Assigned to TRIDENT GROWTH FUND, LP reassignment TRIDENT GROWTH FUND, LP SECURITY AGREEMENT Assignors: AUSAM BIOTECHNOLOGIES, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Definitions

  • the present invention relates to methods of detecting an early stage of renal disease and/or renal complications of a disease.
  • the invention also relates to preventing and treating the disease.
  • Specific proteinuria and in particular, albuminuria (micro- and macro-), is a marker of disease including renal disease (glomerulonephritis, bacterial and viral glomerulonephritides, IgA nephropathy and Henoch-Schönlein Purpura, membranoproliferative glomerulonephritis, membranous nephropathy, Sjögren's syndrome, diabetic nephropathy, nephrotic syndrome (minimal change disease, focal glomerulosclerosis and related disorders), acute renal failure, acute tubulointerstitial nephritis, pyelonephritis, GU tract inflammatory disease, Pre-clampsia, renal graft rejection, leprosy, reflux nephropathy, nephrolithiasis), genetic renal disease (medullary cystic, medullar sponge, polycystic kidney disease (autosomal dominant polycystic kidney disease, autosomal rece
  • Kidney disease may result from bacterial infection, allergies, congenital defects, stones, antibiotics, immunosuppressives, antineoplastics, nonsteroidal anti-inflammatory drugs, analgesics, heavy metals, tumors, chemicals.
  • proteins including albumin
  • proteins are normally excreted as a mixture of native protein and fragments that are specifically produced during renal passage. Osicka T. M. et al., Nephrology 2:199-212 (1996). Proteins are heavily degraded during renal passage by post-glomerular (basement membrane) cells, which may include tubular cells. Lysosomes in renal tubular cells may be responsible for the breakdown of proteins excreted during renal passage (see, FIG. 1). The breakdown products are excreted into the tubular lumen. In normal individuals, most of the albumin in the urine is fragmented.
  • the invention provides for the use of a lysosome-activating compound in reactivating lysosomes or processes that direct substrates to the lysosome or products away from the lysosome.
  • a lysosome-activating compound in reactivating lysosomes or processes that direct substrates to the lysosome or products away from the lysosome.
  • lysosome activity or intracellular processes directing substrates to lysosomes is reduced as in kidney disease, more of the high molecular weight, and substantially full length filtered protein including albumin appears in the urine.
  • conventional drugs, the ACE inhibitor ramipril and the anti-glycation agent aminoguanidine are able to prevent changes in the renal lysosomal processing of protein.
  • the invention is directed to a method for treating a person suffering from a disease in which a diseased state is indicated by specific proteinuria, by administering a therapeutically effective amount of the treatment agent, obtained according to the above method, to a person in need thereof.
  • the treatment agent is a lysosome-activating compound.
  • a method of preventing or treating kidney disease including administering an effective amount of lysosome-activating compound to a subject in need thereof.
  • composition comprising a lysosome-activating compound and a carrier.
  • a method of screening a multiplicity of compounds to identify a compound capable of activating or processes that direct substrates to the lysosome or products away from the lysosome including the steps of:
  • the disease sought to be treated includes nephropathy, diabetes insipidus, diabetes type I, diabetes II, renal disease (glomerulonephritis, bacterial and viral glomerulonephritides, IgA nephropathy and Henoch-Schönlein Purpura, membranoproliferative glomerulonephritis, membranous nephropathy, Sjögren's syndrome, nephrotic syndrome (minimal change disease, focal glomerulosclerosis and related disorders), acute renal failure, acute tubulointerstitial nephritis, pyelonephritis, GU tract inflammatory disease, Pre-clampsia, renal graft rejection, leprosy, reflux nephropathy, nephrolithiasis), genetic renal disease (medullary cystic, medullar sponge, polycystic kidney disease (autosomal dominant polycys
  • the invention can be used in conjunction with a method of diagnosing early stage of renal disease and/or renal complications of a disease, comprising:
  • the invention can be used for determining a treatment agent (such as a lysosome-activating compound) for renal disease and/or renal complications of a disease, comprising:
  • FIG. 1 illustrates the progress of filtered intact albumin into tubular cells and breakdown of albumin to provide excreted albumin fragments.
  • FIG. 2 illustrate a representative profile of ( 3 H) HSA in (a) urine and (b) plasma collected from normal, healthy volunteers by size exclusion chromatography.
  • Urine contains mostly fragmented albumin.
  • plasma contains mostly intact albumin.
  • FIG. 3 illustrates urine from normal, healthy volunteer showing a fragmented albumin peak, but no intact albumin peak from size exclusion chromatography.
  • FIG. 4 illustrates urine from a diabetic patient showing both intact and fragmented albumin peaks from size exclusion chromatography.
  • FIG. 5 illustrates a HPLC profile of albumin alone.
  • FIG. 6 illustrates the HPLC profile of plasma from normal, healthy volunteer showing albumin peaks.
  • FIG. 7 shows the HPLC profile of urine from normal, healthy volunteer with fragmented products of albumin but no intact albumin peak.
  • FIG. 8 shows the HPLC profile of a urine sample from a normoalbuminuric diabetic patient showing albumin breakdown products and a small-modified albumin peak at approximately 39-44 minutes retention time.
  • FIG. 9 shows the HPLC profile of urine from a normoalbuminuric diabetic patient showing signs of kidney failure and the presence of the characteristic spiked albumin peak at approximately 39-44 minutes retention time.
  • FIG. 10 illustrates a HPLC profile of a normoalbuminuric diabetic patient showing signs of kidney failure and the presence of the characteristic spiked modified albumin peak at approximately 39-44 minutes retention time.
  • FIG. 11 illustrates a HPLC of a macroalbuminuric diabetic patient showing high levels of the normal albumin as well as the characteristic spiked appearance at approximately 39-44 minutes retention time.
  • FIG. 12 illustrates a longitudinal study of a patient in which the modified protein was detected at a time prior to onset of diabetic nephropathy, indicating predisposition to diabetic nephropathy, and the delay in treatment caused by relying on conventional RIA methods.
  • FIG. 13 illustrates a longitudinal study of a patient in which the modified protein was detected at a time prior to onset of diabetic nephropathy, indicating predisposition to diabetic nephropathy, and the delay in treatment caused by relying on conventional RIA methods.
  • FIG. 14 illustrates a longitudinal study of a patient in which the modified protein was detected at a time prior to onset of diabetic nephropathy, indicating predisposition to diabetic nephropathy, and the delay in treatment caused by relying on conventional RIA methods.
  • FIG. 15 shows the HPLC chromatogram used as a criterion of purity of the modified albumin of Example 4.
  • FIG. 16 illustrates ( 3 H)HSA in urine collected from a microalbuminuric type I diabetic patient by size exclusion chromatography.
  • Urine contains mostly fragmented albumin.
  • Plasma contains only intact albumin.
  • Conventional RIA human albumin ordinate measures only intact albumin and not fragments.
  • FIG. 17 illustrates the size exclusion profiles of ( 3 H)HSA in urine from four different patients with varying albumin excretion rate (AER) as measured by conventional RIA.
  • AER albumin excretion rate
  • proteins including major plasma proteins such as albumin and immunoglobulin
  • tubular cells lie beyond the kidney filter and come in direct contact with the primary filtrate.
  • proteins are internalized by the tubular cells, they are directed towards the lysosomes, where they are partially degraded to various size fragments, and then regurgitated to outside the cell. These regurgitated fragments, of which there may be at least 60 different fragments generated from any one particular type of protein, are then excreted into the urine.
  • the drugs may also be useful in other renal diseases where lysosomal activities are affected, or in diabetes without renal complications in situations where lysosomal activity is turned off in non-renal tissues.
  • Such drugs include antiproliferative drugs, such as anticancer drugs or antibodies to neutralize TGF-beta.
  • the invention is also directed to a method of determining a treatment agent for renal disease and/or renal complications of a disease, comprising: (a) administering to a person an agent that is suspected of being able to treat the disease; (b) obtaining a urine sample from the person; and (c) assaying for the protein in the sample, wherein decreasing amount of the protein over time indicates that the agent is a treatment agent for the disease.
  • the treatment agent may be a lysosome-activating agent that may act directly or indirectly to activate lysosome, and thereby cause the lysosome to digest post-glomerular filtered proteins, which is a sign of a healthy kidney.
  • PKC protein kinase C
  • a lysosome-activating compound for use in reactivating lysosomes or processes that direct substrates to the lysosome or products away from the lysosome.
  • composition comprising a lysosome-activating compound and a carrier.
  • a method of preventing or treating kidney disease including administering an effective amount of a lysosome-activating compound to a subject.
  • a method of screening a multiplicity of compounds to identify a compound capable of activating lysosomes or processes that direct substrates to the lysosome or products away from the lysosome said method including the steps of: (a) exposing said compound to a lysosome and assaying said compound for the ability to activate a lysosome wherein said lysosome when activated has a changed activity; (b) assaying for the ability to restore a cellular process to substantially normal levels in kidney tissue, wherein said kidney tissue has a low lysosome activity; and/or (c) assaying for the ability to restore tissue turnover to substantially normal levels in kidney tissue, wherein said kidney tissue has low lysosome activity.
  • Lysosomes are associated with the breakdown of proteins, particularly albumin, in the kidney (see, FIG. 1). In cases of microalbuminuria, substantial amounts of albumin escape lysosomal breakdown possibly due to a deactivated lysosome. Restoration of lysosomal breakdown restores the balance in the kidney of cellular processes and tissue turnover.
  • a lysosome-activating compound is a compound that acts directly or indirectly on the lysosome. By acting indirectly, the compound may act on a component that influences the activity of the lysosome. Nevertheless, the outcome results in an activation of the lysosome, thereby providing enhanced protein breakdown.
  • composition comprising a lysosome-activating compound and a carrier.
  • the composition may be a physiologically acceptable or pharmaceutically acceptable composition. However, it will be a composition that allows for stable storage of the lysosome-activating compound. Where the composition is a pharmaceutically acceptable composition, it may be suitable for use in a method of preventing or treating kidney disease.
  • a method of preventing or treating kidney disease including administering an effective amount of a lysosome-activating compound to a subject.
  • the lysosome-activating compound may act by reactivating the lysosome so that cellular processes and tissue turnover are restored fully or in part, thereby resulting in the kidney being restored partially or fully.
  • administering a lysosome-activating compound to an animal having kidney disease may restore lysosome activity fully or in part.
  • Methods of administering may be oral or parenteral.
  • Oral may include administering with tablets, capsules, powders, syrups, etc.
  • Parenteral administration may include intravenous, intramuscular, subcutaneous or intraperitoneal routes. Dosages for administration of the compounds of the invention may be calculated by those of skill in the art (see, Goodman & Gilman, The Pharmacological Basis of Therapeutics, 8th Ed. (Pergamon Press, N.Y., 1990); and The Merck Index, 11 th Ed. (Merck and Co., Inc., Rahway, N.J. 1989); both incorporated herein by reference).
  • the changed activity of the lysosome is preferably a change that enhances the activity of the lysosome so that albumin breakdown is improved.
  • the ability to not only activate lysosome but also improve cellular processes and/or tissue turnover is a characteristic of the most desirable lysosome-activating compound.
  • “Fragmented protein or fragment albumin” includes post-glomerular breakdown products after chemical, enzymatic or physical breakdown that occurs during renal passage. These components have a reduced size and/or may have changed hydrophobicity.
  • “Intact albumin, modified albumin, or modified form of albumin” as used herein means a compound having similar size and structural characteristics to native albumin, wherein the amino acid sequence is substantially the same as the native albumin. It is preferably a filtered intact protein. It elutes at or near the same position as native albumin on high-pressure liquid chromatography (HPLC) (FIG. 5).
  • HPLC high-pressure liquid chromatography
  • the structure has been modified biochemically either by minor enzyme mediated modification or addition to its basic structure and/or physically through a change in its three dimensional structure so that it escapes detection by conventionally used anti-albumin antibodies.
  • Biochemical modification may be made by enzymes such as endo- or exo- peptidases.
  • the 3D structure of albumin may have been altered in some way. Ligands may have bound to the albumin, or it may be any combination of these.
  • the modified albumin detected in the method of the invention is not detectable by current and conventional radioimmunoassays using
  • Conventional anti-albumin antibodies can be purchased from any purveyor of immunochemicals.
  • monoclonal antibody catalog numbers A6684 clone no. HSA-11
  • A2672 clone no. HSA-9
  • liquid whole serum, lyophilized fractionates, liquid IgG fraction, and the monoclonal antibodies in liquid ascites fluids form can be obtained from Sigma, St. Louis, Mo., as found in the Immunochemicals section at pages 1151-1152 in the 1994 Sigma—Biochemicals Organic Compounds for Research and Diagnostic Reagents catalog.
  • intact/modified albumin includes albumin that is substantially full-length, fragmented, chemically modified, or physically modified.
  • intact/modified albumin is meant to indicate albumin that is less than, equal to, or greater in molecular weight than the full-length albumin, and elutes at or near the native albumin position in a separation medium, such as chromatography, preferably HPLC, and most preferably hydrophobicity HPLC.
  • fragmented albumin is meant to refer to the fragment of albumin that is not detected by conventional anti-albumin antibody, and its presence is detected in diagnosing an early stage of renal disease and/or renal complications of a disease. The detection of the presence of intact/modified albumin is an indication of a predisposition to renal disease.
  • “Intact protein, modified protein or modified form of a protein” as used herein includes those forms of substantially full-length protein which are undetectable by conventional radioimmunoassay.
  • the protein includes, but is not limited to, albumins, globulins ( ⁇ -globulin( ⁇ 1 -globulin, ⁇ 2 -globulin), ⁇ -globulins, ⁇ -globulins), euglobulins, pseudoglobulin I and II, fibrinogen, ⁇ 1 acid glycoprotein (orosomucoid), ⁇ 1 glycoprotein, ⁇ 1 lipoproteins, ceruloplasmin, ⁇ 2 19S glycoprotein, ⁇ 1 transferrin, ⁇ 1 lipoprotein, immunoglobulins A, E, G, and M, protein hormones including growth hormone, insulin, parathyroid hormone and other proteins including horseradish peroxidase, lactate dehydrogenase, glucose oxidase, myoglobin, and lysozyme.
  • Kidney disease as used herein includes any malfunction of the kidney. Kidney disease may be identified by the presence of intact or modified albumin in the urine. Preferably, an early diagnosis of the kidney disease may be made by detecting the presence of modified protein in the urine, or an increase in the modified protein in the urine over time.
  • Low lysosome activity as used herein is compared against normal levels of lysosome activity and/or lysosome machinery that traffics protein to the lysosome in a normal individual. The activity is insufficient for the lysosome to fragment proteins so that intact protein is excreted at a greater amount than at normally low levels.
  • “Lysosome-activating compound” as used herein refers to a compound that is beneficial to reactivation of the lysosome.
  • the compound may work directly or indirectly on the lysosome resulting in activation of lysosomal function.
  • These compounds may be selected from the group including, but not limited to, anticancer compounds, antiproliferation compounds, paracetamol, insulin vitamin A (retinoic acid) or derivatives of retinol, or compounds, including antibodies, to neutralize TGF-beta.
  • Aminoguanidine and ramipril which have been previously thought to have different mechanism of action, seem to prevent similar diabetes-induced changes in lysosomal processing either through their similar effects on enzyme activity within the lysosome or through their similar effects on the trafficking of molecules to and from the lysosome.
  • Microalbuminuria is a condition where an individual excretes greater than 200 ⁇ g albumin/min in the urine as measured by conventional radioimmunoassay (RIA).
  • Microalbuminuria is a condition where an individual excretes at least 20 ⁇ g albumin/min in the urine as measured by conventional radioimmunoassay (RIA). RIA measures down to 15.6 ng/ml and is able to measure albumin in urine of normal subjects who have clearance of less than 6 ⁇ g/min. However, when albumin excretion exceeds 20 ⁇ g/min, treatment of the kidney disease is limited and full recovery is difficult from this point.
  • RIA radioimmunoassay
  • “Microalbuminuric” as used herein is a condition when albumin is detected in the urine at an excretion rate of at least 20 ⁇ g/min as measured by conventional RIA.
  • “native” and “unmodified” are used interchangeably to describe a protein that is naturally found in an organism, preferably a human, which has not been modified by the filtering process of the renal glomeruli.
  • Normal individual as used herein is an individual who does not have a disease in which intact protein found in urine is an indicator of the disease.
  • the disease is kidney disease.
  • Normal levels of lysosome activity are levels of lysosome activity found in undiseased kidney of a normal individual.
  • Normal albuminuric as used herein means a condition where albumin is excreted in the urine and is not detectable by RIA, or less than 20 ⁇ g/min (as measured by RIA) is excreted.
  • Propensity for a disease means that a disease may result in an individual as judged by a determination of the presence and excretion rate of a modified protein such as modified albumin.
  • Proteinuria as used herein is the existence of protein in the urine, usually in the form of albumin, a protein that is soluble in water and can be coagulated by heat.
  • specific proteinuria refers to the existence of a particular protein in the urine.
  • Radioimmunoassay as used herein is a method for detection and measurement of substances using radioactively labeled specific antibodies or antigens.
  • Reactivation of the lysosome includes an activation of lysosome activity preferably so that breakdown of proteins, particularly albumin, is increased compared with an inactivated state of the lysosome.
  • Restore means to restore in full or in part so that the component being restored has an improved function compared with its previous function.
  • the “sum of intact and intact modified protein” as used herein refers to the total amount of intact protein, and intact modified protein present in a biological sample.
  • Total protein refers to a particular filtered protein present in native, unmodified, modified or fragmented form that is excreted in urine. It includes protein that is not detected by conventional radioimmunoassay or conventional methods, which are currently available to detect the protein. Preferably the protein is albumin.
  • the diseases to be treated include, but are not limited to renal disease (glomerulonephritis, bacterial and viral glomerulonephritides, IgA nephropathy and Henoch-Schönlein Purpura, membranoproliferative glomerulonephritis, membranous nephropathy, Sjögren's syndrome, diabetic nephropathy, nephrotic syndrome (minimal change disease, focal glomerulosclerosis and related disorders), acute renal failure, acute tubulointerstitial nephritis, pyelonephritis, GU tract inflammatory disease, pre-clampsia, renal graft rejection, leprosy, reflux nephropathy, nephrolithiasis), genetic renal disease (medullary cystic, medullar sponge, polycystic kidney disease (autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney
  • Kidney disease may result from bacterial infection, allergies, congenital defects, stones, antibiotics, immunosuppressives, antineoplastics, nonsteroidal antiinflammatory drugs, analgesics, heavy metals, tumors, chemicals.
  • a method for determining a propensity for or early diagnosis of renal disease and/or renal complications of a disease includes determining a change in the albumin content in a urine sample.
  • the disease may be a kidney disease, although not necessarily limited to a kidney disease.
  • albumin is used herein only as an example of a protein to be detected in urine.
  • albumin in a patient is analyzed by conventional RIA, it is expected that a normoalbuminuric patient or normal individual would have albumin in the urine in the range of 3-10 ⁇ g/min in young people and greater in older people.
  • normoalbuminuric patients also show levels of albumin in the urine if measured by HPLC. Applicant has found that these levels may be in the order of 5 ⁇ g/min.
  • the level of intact/modified albumin will increase to microalbuminuria levels in the order of 20 to 200 ⁇ g/min as determined by RIA.
  • a patient suspected of having diabetic kidney disease will not show signs of kidney degeneration until well after 10 to 15 years when albumin is detected by currently available methods such as RIA methods.
  • Urinary excretion rates of at least 20 ⁇ g/min may be detected by RIA when an individual enters a microalbuminuric state. Again, by observing the excretion of modified albumin, a change in the kidney and possibly onset of a kidney disease may be detected.
  • a normoalbuminuric subject, or normoalbuminuric diabetic patient may continue to have a low albumin excretion rate of less than 20 ⁇ g/min as determined by RIA, for many years.
  • the presence of albumin in the urine is a sign that functions of the kidney may be impaired. Once this level begins to change, treatment may be initiated.
  • albumin In a normal individual a small amount of albumin is detectable in the urine. Total filtered albumin appears mainly as fragmented albumin in urine. Some albumin may be detected in normoalbuminuric individuals. However, the excretion rate of albumin in urine in a normoalbuminuric individual may be as low as 5 ⁇ g/min. This level is generally detectable by RIA.
  • the modified protein of the invention can be detected by a variety of methods that are well-known in the art, including, but not limited to chromatography, electrophoresis and sedimentation, or a combination of these, which are described in Karger B L, Hancock W S (eds.) High Resolution Separation and Analysis of biological Macromolecules. Part A Fundamentals in Methods in Enzymology, Vol. 270, 1996, Academic Press, San Diego, Calif., USA; Karger B L, Hancock W S (eds.) High Resolution Separation and Analysis of biological Macromolecules. Part B Applications in Methods in Enzymology, Vol.
  • the electrophoresis method includes, but is not limited to, moving-boundary electrophoresis, zone electrophoresis, and isoelectric focusing.
  • the chromatography method includes, but is not limited to, partition chromatography, adsorption chromatography, paper chromatography, thin-layer chromatography, gas-liquid chromatography, gel chromatography, ion-exchange chromatography, affinity chromatography, and hydrophobic interaction chromatography.
  • the method is a sizing gel chromatography and hydrophobic interaction chromatography. More preferably, the method is hydrophobic interaction chromatography using a HPLC column.
  • the modified protein can also be detected by the use of specific albumin dyes. Such methods are described by Pegoraro et al., American Journal of Kidney Diseases 35(4): 739-744 (April 2000), the entire disclosure of which is hereby incorporated by reference.
  • the modified albumin, as well as the whole albumin is detectable by this dye method to provide the sum of modified albumin and whole or intact albumin.
  • This detection method may be used with or without an initial separation of the albumin components from urine.
  • Such dyes normally do not detect fragments ⁇ 10,000 in molecular weight, but will detect the modified albumin.
  • a dye such as Albumin Blue 580 is used.
  • Such dyes are naturally non-fluorescent, but fluoresce on binding to intact albumin as well as the modified albumin, but do not bind to globulins. Therefore, globulins do not interfere with the assay so that measurements can be made in unfractionated urine.
  • a normoalbuminuric diabetic patient has almost undetectable levels of modified or fragments of albumin when analyzed by conventional RIA. They appear to be normal. However, when the urine is tested by HPLC, the levels of modified albumin are much greater than found in a normal individual. This difference in albumin may be attributed to the inability of conventional RIA's to adequately detect all albumin (total albumin) in intact or modified forms. Thus, HPLC is preferred for generating a fragmentation profile.
  • a fragmentation profile on HPLC is characterized by a series of peaks representing a number of species of albumin as fragments or in intact or modified forms.
  • the method of determining a propensity for or early diagnosis of a kidney disease in a subject is determined before the subject becomes microalbuminuric.
  • Measuring albumin content in a sample by an HPLC method of the present invention may provide different results from its measurement by conventional RIA.
  • a low level of albumin is observed in normal individuals.
  • the level of modified albumin begins to be detected and its level increases, and progresses toward microalbuminuria then a patient can be determined to have a propensity for kidney disease.
  • the HPLC generated fragmentation profile is characterized by the absence of a peak in a region where full-length native albumin elutes. Instead, multiple fragmented albumin is detectable.
  • a pure protein product (unmodified) produces essentially a single peak.
  • albumin was observed to elute in the range of 39-44 minutes (FIG. 5).
  • a normal individual would provide a distinct fragmentation profile indicative of an absence of kidney disease or no propensity for a kidney disease.
  • an increasing amount of modified albumin first, and then native form later are detectable.
  • the fragmentation profile begins to change and more products in the region of full-length albumin manifests as additional spikes or an enlarged peak indicative of more intact/modified albumin in the urine.
  • the modified albumin may appear in a region where native albumin elutes but may be manifest as multiple peaks indicating the presence of multiple forms of modified albumin.
  • the propensity for kidney disease may be measured by determining the presence of or identifying at least one species of modified albumin. This may be determined or identified by the presence of a specific peak on a HPLC profile, preferably the peak is within the range of position that corresponds to the elution position of the native albumin.
  • a HPLC column for detecting modified albumin or unmodified albumin may be a hydrophobicity column, such as Zorbax 300 SB-CB (4.6 mm ⁇ 150 mm).
  • a 50 ⁇ l sample loop may be used.
  • Elution solvents suitable for HPLC in detecting albumin and its breakdown products may include standard elution solvents such as acetonitrile solvents.
  • a buffer of water/1% trifluoro acetic acid (TFA) followed by a buffer of 60% acetonitrile/0.09% TFA may be used.
  • TFA trifluoro acetic acid
  • a gradient of 0 to 100% of a 60% acetonitrile/0.09% TFA has been found to be suitable.
  • Suitable HPLC conditions for a hydrophobicity column may be as follows:
  • the wavelength used in HPLC may be approximately 214 nm.
  • Modified albumin may elute between 39-44 minutes (FIG. 5). Albumin fragments may elute much earlier, mainly at less than 20 minutes.
  • the method for determining the propensity for kidney disease is applicable to any individual.
  • Kidney disease may be caused by a number of factors including bacterial infection, allergic, congenital defects, stones, tumors, chemicals or from diabetes.
  • the method is applicable for determining a propensity for kidney disease in diabetic patients that may progress to a kidney disease.
  • the individual is a normoalbuminuric diabetic.
  • normal individuals may be monitored for propensity for the disease by determining increased levels of intact or modified albumin in the urine.
  • the method of the invention can be carried out using non-antibody separation procedures as described above.
  • antibody specific for modified protein may also be used to detect the presence of the modified protein.
  • the antibody to the modified protein may be obtained using the following method.
  • the procedure is described specifically for albumin by way of example only, and can be readily applied to antibody production against any other protein in the urine.
  • the method seeks to determine which modified albumin molecule is the most sensitive marker to identify diabetic patients, for example, who will progress to kidney complications.
  • the modified albumin is characterized by carrying out a quantitative separation of the modified albumin molecules, such as by preparative HPLC.
  • the modified proteins are analyzed for ligand binding, such as glycation.
  • amino acid sequence of the individual modified protein is determined, preferably by mass spectrometry using methods described in Karger B L, Hancock W S (eds.) High Resolution Separation and Analysis of biological Macromolecules. Part A Fundamentals in Methods in Enzymology, Vol. 270, 1996, Academic Press, San Diego, Calif., USA; or Karger B L, Hancock W S (eds.) High Resolution Separation and Analysis of biological Macromolecules. Part B Applications in Methods in Enzymology, Vol. 271, 1996, Academic Press, San Diego, Calif., USA, for example, which references are incorporated herein by reference in their entirety. In a preferred embodiment, there may be about 3 to 4 modified albumin species.
  • the method of generating antibody against the modified albumin seeks to develop a diagnostic immunoassay for the modified albumin that predicts those diabetic patients, for example, that progress to kidney complications. To accomplish this, sufficient quantities of modified albumin is prepared by HPLC. Antibodies are made by sequential injection of the modified albumin in an animal such as a rabbit, to generate good titer, and the antibodies are isolated using conventional techniques using methods described in Goding J W, Monoclonal Antibodies: Principles and Practice.
  • the obtained antibodies may be polyclonal antibodies or monoclonal antibodies.
  • At least one species of a modified albumin is isolated and identified for use in determining a propensity for kidney disease.
  • the isolated species may be used to generate antibodies for use in immunoassays.
  • the antibodies may be tagged with an enzymatic, radioactive, fluorescent or chemiluminescent label.
  • the detection method may include, but is not limited to radioimmuoassay, immunoradiometric assay, fluorescent immunoassay, enzyme linked immunoassay, and protein A immunoassay.
  • the assays may be carried out in the manner described in Goding J W, Monoclonal Antibodies: Principles and Practice. Production and Application of Monoclonal Antibodies in Cell Biology, Biochemistry and Immunology.
  • kits for rapidly and accurately determining the presence or absence of modified protein such as modified albumin, in a sample quantitatively or non-quantitatively as desired.
  • modified protein such as modified albumin
  • Each component of the kit(s) may be individually packaged in its own suitable container.
  • the individual container may also be labeled in a manner, which identifies the contents.
  • the individually packaged components may be placed in a larger container capable of holding all desired components.
  • Associated with the kit may be instructions, which explain how to use the kit. These instructions may be written on or attached to the kit.
  • the invention is also directed to a method of determining a treatment agent for renal disease and/or renal complications of a disease, comprising:
  • the treatment agent may be a lysosome activating agent that may act directly or indirectly to activate lysosome, and thereby cause the lysosome to digest post-glomerular filtered proteins, which is a sign of a healthy kidney.
  • PKC protein kinase C
  • a lysosome-activating compound for use in reactivating lysosomes or processes that direct substrates to the lysosome or products away from the lysosome.
  • composition comprising a lysosome-activating compound and a carrier.
  • a method of preventing or treating kidney disease including administering an effective amount of a lysosome-activating compound to a subject.
  • a method of screening a multiplicity of compounds to identify a compound capable of activating lysosomes or processes that direct substrates to the lysosome or products away from the lysosome including the steps of:
  • Lysosomes may be associated with the breakdown of proteins, particularly albumin, in the kidney. In cases of microalbuminuria, substantial amounts of albumin escape lysosomal breakdown possibly due to a deactivated lysosome. Restoration of lysosomal breakdown may restore the balance in the kidney of cellular processes and tissue turnover.
  • a lysosome-activating compound may be a compound that acts directly or indirectly on the lysosome. By acting indirectly, the compound may act on a component, which influences the activity of the lysosome. Nevertheless, the outcome results in an activation of the lysosome, thereby providing enhanced protein breakdown.
  • composition comprising a lysosome-activating compound and a carrier.
  • the composition may be a physiologically acceptable or pharmaceutically acceptable composition. However, it will be a composition which allows for stable storage of the lysosome activating compound. Where the composition is a pharmaceutically acceptable composition, it may be suitable for use in a method of preventing or treating kidney disease.
  • a method of preventing or treating kidney disease including administering an effective amount of a lysosome-activating compound to a subject.
  • the lysosome-activating compound may act by reactivating the lysosome so that cellular processes and tissue turnover are restored fully or in part, thereby resulting in the kidney being restored partially or fully.
  • administering a lysosome activating compound to an animal having kidney disease may restore lysosome activity fully or in part.
  • Methods of administering may be oral or parenteral.
  • Oral may include administering with tablets, capsules, powders, syrups, etc.
  • Parenteral administration may include intravenous, intramuscular, subcutaneous or intraperitoneal routes.
  • the changed activity of the lysosome is preferably a change which enhances the activity of the lysosome so that albumin breakdown is improved.
  • the ability to not only activate lysosome but also improve cellular processes and/or tissue turnover is a characteristic of the most desirable lysosome activating compound.
  • a method for preventing kidney disease in a subject including:
  • H[HSA] Human Serum Albumin
  • Tritium radioactivity was determined in 1 ml aqueous samples with 3 ml scintillant and measured on a Wallac 1410 liquid scintillation counter (Wallac Turku, Finland).
  • FIG. 2 illustrates the distribution of albumin in urine and in plasma.
  • Example 1 3 H[HSA] as used in Example 1 was injected into a normal, healthy volunteer and a diabetic patient. Samples of urine were collected and 3 H[HSA] was determined as in Example 1.
  • the normal, healthy volunteer (FIG. 3) shows the excretion of fragments of albumin on a size exclusion chromatography as performed in Example 1.
  • the diabetic patient (FIG. 4) shows the presence of substantially full-length and fragmented albumin on size exclusion chromatography.
  • excretion rates of albumin detectable by these methods were in the order of 5 ⁇ /min (control) and 1457 ⁇ /min (diabetic).
  • Urine samples were collected from normal, healthy volunteer, normoalbuminuric diabetic patients and from macroalbuminuric patients. Urine was collected midstream in 50 ml urine specimen containers. The urine was frozen until further use. Prior to HPLC analysis the urine was centrifuged at 5000 g.
  • a wavelength of 214 nm was used.
  • Urine from microalbuminuric patient which had an intact albumin concentration of 43.5 mg/L as determined by turbitimer was initially filtered through a 30 kDa membrane to separate the modified albumin from low molecular weight ( ⁇ 30,000) protein fragments in urine.
  • the material that was retained by the filter gave a yield of intact albumin of 27.4 mg/L as determined by turbitimer assay.
  • This retained material was then subjected to size exclusion chromatography on Sephadex G100.
  • the material collected was the peak fraction that coelutes with intact albumin. This material gave a yield of 15.2 ml/L of albumin as determined by the turbitimer method.
  • FIG. 5 illustrates a HPLC profile of albumin alone. Essentially a single peak which elutes at approximately 39-44 minutes retention time was obtained.
  • FIG. 6 illustrates a HPLC profile of plasma showing a distinct albumin peak at approximately 39-44 minutes as well as other peaks corresponding to other plasma proteins.
  • FIG. 7 illustrates a HPLC profile of a normal, healthy volunteer showing no albumin peak in the urine sample. This individual breaks down the albumin excreted into the urine possibly via an active lysosome. Substantial fragmented products were evident showing prominence of some species, particularly of a species at approximately less than 14.5 minutes retention time.
  • FIG. 9 Another urine sample from normoalbuminuric diabetic patient (with albumin excretion rate of 17.04 ⁇ g/min) was analyzed (FIG. 9). RIA tests show albumin excreted in the urine for this patient. However, on HPLC (FIG. 9) an albumin or modified albumin peak is evident at approximately 39-44 minutes retention time. Whereas conventional test indicates the presence of ⁇ 6 mg/l of albumin in the urine sample, the method of the invention showed that the true albumin content in the urine sample was 81.3 mg/l. Treatment for the disease should have begun on this individual. This peak begins to show a multiple peaked appearance. A smaller peak corresponding to intact albumin shows that modified albumin may represent the peak at 39-44 minutes. The presence of this albumin peak compared with the profile of a normal, healthy volunteer having no albumin peak shows a change in the detectable levels of the amount of intact/modified albumin. This may signal a propensity for a kidney disease.
  • a further urine sample from a normoalbuminuric diabetic patient (with an albumin excretion rate of 4.37 ⁇ g/min) was analyzed, and the HPLC profile is illustrated in FIG. 10. Again, modified albumin was detected at approximately 39-44 minutes retention time showing multiple peaks. This patient again did register normal albumin by RIA. Whereas conventional test indicates the presence of ⁇ 6 mg/l of albumin in the urine sample, the method of the invention showed that the true albumin content in the urine sample was 491 mg/l. Treatment for the disease should have begun on this individual. It is clear that modified albumin assessment is necessary to identify these changes. This patient would be determined to have a propensity for kidney disease. As kidney disease progresses, the modified albumin peak will continue to increase.
  • FIG. 11 This is shown in FIG. 11 where a urine sample of a macroalbuminuric patient was analyzed. A quite significant albumin peak at approximately 39-44 minutes retention time showing multiple peaks was evident. The patient's albumin content was 1796 mg/l. Treatment for this individual is in progress.
  • the method of the invention results in early detection of a propensity for a renal disease as illustrated by the longitudinal studies in FIGS. 12 - 14 .
  • FIGS. 12 - 14 show situations in which the ACE inhibitor treatment for diabetes was begun later than it should have had the modified albumin detection method of the invention been used. Detecting modified protein using the method according to the invention is a more effective method for predicting the onset of a renal disease than using conventional RIA.
  • FIG. 16 illustrates ( 3 H)HSA in urine collected from a microalbuminuric type I diabetic patient by size exclusion chromatography.
  • Urine contains mostly fragmented albumin.
  • Plasma contains only intact albumin.
  • Conventional RIA human albumin ordinate measures only intact albumin and not fragments.
  • FIG. 17 shows that in renal disease in type I diabetic patients the severity of the disease as measured by albuminuria is associated with the increased presence of intact albumin in urine.
  • FIG. 17 illustrates the size exclusion profiles of ( 3 H)HSA in urine from four different patients with varying albumin excretion rate (AER) as measured by conventional RIA.
  • AER albumin excretion rate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
US09/893,346 1998-12-21 2001-06-28 Method for kidney disease treatment by drug intervention Abandoned US20020012906A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/893,346 US20020012906A1 (en) 1998-12-21 2001-06-28 Method for kidney disease treatment by drug intervention
US10/721,351 US20040106155A1 (en) 1998-12-21 2003-11-26 Method for kidney disease treatment by drug intervention

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPP7843 1998-12-21
AUPP7843A AUPP784398A0 (en) 1998-12-21 1998-12-21 Kidney disease detection and treatment
US09/415,217 US6447989B1 (en) 1998-12-21 1999-10-12 Kidney disease detection and treatment
PCT/IB1999/002029 WO2000037944A1 (en) 1998-12-21 1999-12-20 Kidney disease detection and treatment
IBPCT/IB99/02029 1999-12-20
US09/893,346 US20020012906A1 (en) 1998-12-21 2001-06-28 Method for kidney disease treatment by drug intervention

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/415,217 Continuation-In-Part US6447989B1 (en) 1998-12-21 1999-10-12 Kidney disease detection and treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/721,351 Continuation US20040106155A1 (en) 1998-12-21 2003-11-26 Method for kidney disease treatment by drug intervention

Publications (1)

Publication Number Publication Date
US20020012906A1 true US20020012906A1 (en) 2002-01-31

Family

ID=25645955

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/893,346 Abandoned US20020012906A1 (en) 1998-12-21 2001-06-28 Method for kidney disease treatment by drug intervention
US09/892,797 Expired - Fee Related US6589748B2 (en) 1998-12-21 2001-06-28 Method for kidney disease detection and treatment
US10/721,351 Abandoned US20040106155A1 (en) 1998-12-21 2003-11-26 Method for kidney disease treatment by drug intervention

Family Applications After (2)

Application Number Title Priority Date Filing Date
US09/892,797 Expired - Fee Related US6589748B2 (en) 1998-12-21 2001-06-28 Method for kidney disease detection and treatment
US10/721,351 Abandoned US20040106155A1 (en) 1998-12-21 2003-11-26 Method for kidney disease treatment by drug intervention

Country Status (13)

Country Link
US (3) US20020012906A1 (enExample)
EP (1) EP1141728B1 (enExample)
JP (2) JP4160263B2 (enExample)
CN (1) CN1331801A (enExample)
AT (1) ATE376187T1 (enExample)
AU (1) AU1674400A (enExample)
BR (1) BR9916407A (enExample)
CA (1) CA2356174A1 (enExample)
DE (1) DE69937368T2 (enExample)
DK (1) DK1141728T3 (enExample)
IL (1) IL143892A0 (enExample)
MX (1) MXPA01006404A (enExample)
WO (1) WO2000037944A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103949A1 (en) * 2000-05-17 2003-06-05 Carpenter Melissa K. Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
US20070020629A1 (en) * 2003-02-13 2007-01-25 Julie Ross Devices for component removal during blood collection, and uses thereof
CN111714517A (zh) * 2020-04-14 2020-09-29 南开大学 一种溶酶体作为制备药物领域的应用
US10830773B2 (en) 2009-12-20 2020-11-10 Astute Medical, Inc. Methods for prognosis of future acute renal injury and acute renal failure
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
US11099194B2 (en) 2013-01-17 2021-08-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP784398A0 (en) 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
AU1674400A (en) 1998-12-21 2000-07-12 Monash University Kidney disease detection and treatment
AU2002305159B2 (en) * 2001-03-28 2007-12-13 Heska Corporation Methods of detecting early renal disease in animals
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
US7482128B2 (en) 2003-03-27 2009-01-27 Heska Corporation Anti-feline albumin antibodies
JP2007521232A (ja) 2003-08-08 2007-08-02 アブジェニックス・インコーポレーテッド 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
US8647660B2 (en) * 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CN102907561A (zh) * 2004-12-30 2013-02-06 希尔氏宠物营养品公司 提高老年动物的生活质量的方法
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
EP1874130A4 (en) * 2005-04-19 2009-04-29 Hills Pet Nutrition Inc METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING NURSE DISEASES
CA2605855A1 (en) * 2005-04-29 2006-11-09 Hill's Pet Nutrition, Inc. Methods for prolonging feline life
CA2608670C (en) * 2005-05-20 2019-03-05 Hill's Pet Nutrition, Inc. Methods for promoting health or wellness in adult animals
WO2007002836A2 (en) * 2005-06-29 2007-01-04 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
CA2619042C (en) * 2005-08-17 2011-03-15 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
AU2008223791B2 (en) * 2007-03-07 2013-10-03 Mosaiques Diagnostics And Therapeutics Ag Method for the standardization of the concentration of analytes in a urine sample
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
EP2535718B1 (en) * 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
AU2008309605A1 (en) * 2007-10-09 2009-04-16 Mosaiques Diagnostics And Therapeutics Ag Polypeptide marker for the diagnosis of prostate cancer
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
JP2011515672A (ja) * 2008-03-19 2011-05-19 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー 腎尿細管の損傷および疾患の診断のための方法およびマーカー
EP2313778B1 (en) * 2008-07-18 2015-01-28 Boston Medical Center Corporation Diagnostics for membranous nephropathy
NZ610356A (en) * 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9057735B2 (en) * 2008-08-29 2015-06-16 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2338054A1 (de) * 2008-09-17 2011-06-29 Mosaiques Diagnostics And Therapeutics AG Nierenzellkarzinom
CN104020284B (zh) * 2008-10-21 2016-08-24 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ628843A (en) * 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2528799T3 (es) * 2008-11-22 2015-02-12 Astute Medical, Inc. Métodos para el pronóstico de insuficiencia renal aguda
WO2010064239A1 (en) 2008-12-04 2010-06-10 Technion Research And Development Foundation Ltd. Apparatus and methods for diagnosing renal disorders
BRPI1007483B1 (pt) * 2009-01-28 2021-11-30 Bio Preventive Medicine Corporation Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5827226B2 (ja) * 2009-08-07 2015-12-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN102792161B (zh) * 2009-08-28 2014-11-12 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后的方法及组合物
EA201290192A1 (ru) 2009-11-07 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2012005210A (es) * 2009-11-07 2012-08-03 Astute Medical Inc Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
DK2666872T3 (en) 2010-02-05 2016-07-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130203074A1 (en) 2010-06-23 2013-08-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012019110A1 (en) * 2010-08-05 2012-02-09 Abbott Laboratories Method and system for managing patient healthcare
DE102010038014B4 (de) * 2010-10-06 2021-10-07 Numares Ag Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung
KR101215759B1 (ko) 2010-11-01 2012-12-26 서울대학교산학협력단 오로소뮤코이드를 포함하는 조성물의 용도
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
CN102854325B (zh) * 2011-07-01 2015-01-07 复旦大学 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20130115640A1 (en) * 2011-11-03 2013-05-09 James A. Tumlin ACTH for Treatment of Kidney Disease
US9689826B2 (en) 2012-03-11 2017-06-27 Technion Research And Development Foundation Ltd. Detection of chronic kidney disease and disease progression
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
JP2016188761A (ja) * 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
CN104007258B (zh) * 2013-09-30 2016-07-06 中国医学科学院基础医学研究所 局灶性节段性肾小球硬化的蛋白标志物
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN104849466A (zh) * 2014-02-14 2015-08-19 张曼 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用
US20170205427A1 (en) * 2014-07-23 2017-07-20 University Of British Columbia Biomarkers for anderson-fabry disease
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN107561175A (zh) * 2017-08-10 2018-01-09 武汉大学 一种肾小球硬化大鼠模型的评价方法
RU2697722C1 (ru) * 2018-12-06 2019-08-19 Ирина Сергеевна Шатохина Способ диагностики активности воспалительного процесса при латентном течении хронического пиелонефрита
CN110632229A (zh) * 2019-09-24 2019-12-31 华兰生物工程重庆有限公司 高效液相色谱仪检测静注人免疫球蛋白(pH4)蛋白质含量的方法
RU2768464C1 (ru) * 2021-04-27 2022-03-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики мембранозной нефропатии как одной из форм хронического гломерулонефрита

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994165A (en) * 1989-02-16 1991-02-19 Cornell Research Foundation, Inc. Liquid junction coupling for capillary zone electrophoresis/ion spray spectrometry

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69221666T2 (de) 1991-05-24 1998-01-15 Wakamoto Pharma Co Ltd Verfahren zur Diagnose von Nierenkrankheiten durch Nachweisung von Albuminfragmenten
JPH0682446A (ja) * 1992-08-31 1994-03-22 Wakamoto Pharmaceut Co Ltd 腎疾患の診断法
DE4336498A1 (de) * 1993-10-26 1995-04-27 Bender & Co Gmbh Verfahren zur Diagnose von Nieren- und Gefäßerkrankungen
US5534431A (en) 1994-02-28 1996-07-09 The Board Of Regents Of The University Of Nebraska Hybridomas and monoclonal antibodies specific for unique determinants of nephropathy-related immunoglobulin G and complexes thereof
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5800998A (en) * 1996-11-12 1998-09-01 Millennium Pharmaceuticals, Inc. Assays for diagnosing type II diabetes in a subject
AU1674400A (en) 1998-12-21 2000-07-12 Monash University Kidney disease detection and treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994165A (en) * 1989-02-16 1991-02-19 Cornell Research Foundation, Inc. Liquid junction coupling for capillary zone electrophoresis/ion spray spectrometry

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103949A1 (en) * 2000-05-17 2003-06-05 Carpenter Melissa K. Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
US20070020629A1 (en) * 2003-02-13 2007-01-25 Julie Ross Devices for component removal during blood collection, and uses thereof
US8603345B2 (en) * 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
US12123882B2 (en) 2009-12-20 2024-10-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10830773B2 (en) 2009-12-20 2020-11-10 Astute Medical, Inc. Methods for prognosis of future acute renal injury and acute renal failure
US11262363B2 (en) 2009-12-20 2022-03-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
US12019080B2 (en) 2013-01-17 2024-06-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11099194B2 (en) 2013-01-17 2021-08-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
US12471843B2 (en) 2017-08-08 2025-11-18 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN111714517A (zh) * 2020-04-14 2020-09-29 南开大学 一种溶酶体作为制备药物领域的应用

Also Published As

Publication number Publication date
JP2006038877A (ja) 2006-02-09
EP1141728B1 (en) 2007-10-17
US20020022236A1 (en) 2002-02-21
JP2002533680A (ja) 2002-10-08
CA2356174A1 (en) 2000-06-29
BR9916407A (pt) 2001-09-25
AU1674400A (en) 2000-07-12
IL143892A0 (en) 2002-04-21
JP4160263B2 (ja) 2008-10-01
DE69937368T2 (de) 2008-07-17
EP1141728A4 (en) 2005-01-12
DK1141728T3 (da) 2008-02-04
ATE376187T1 (de) 2007-11-15
US20040106155A1 (en) 2004-06-03
WO2000037944A1 (en) 2000-06-29
EP1141728A1 (en) 2001-10-10
DE69937368D1 (de) 2007-11-29
JP4388515B2 (ja) 2009-12-24
US6589748B2 (en) 2003-07-08
MXPA01006404A (es) 2003-06-06
CN1331801A (zh) 2002-01-16

Similar Documents

Publication Publication Date Title
US6589748B2 (en) Method for kidney disease detection and treatment
US6447989B1 (en) Kidney disease detection and treatment
US20030003588A1 (en) Method for kidney disease detection by protein profiling
EP2310861B1 (en) Healthy kidney biomarkers
EP1628136A1 (en) Method of diagnosis of disease using copeptin
EP1352238A2 (en) Method for detection of vitamin d metabolites
CA2008360A1 (en) Myocardial infarction immunoassay
US20050191664A1 (en) Method for kidney disease detection
US20060234295A1 (en) Sandwich immunoassay for identifying partial proanp peptides
Nguyen et al. Circulating macroprolactin exhibits molecular heterogeneity and is not exclusively an antibody complex
JPH06502912A (ja) アナライト変異体分析
Arendt et al. Increased endothelin plasma concentrations in patients with coronary artery disease or hyperlipoproteinemia without coronary events
EP1169647B1 (en) Method for analyzing the amount of intraabdominal adipose tissue
CA2393004A1 (en) Method of diagnosing neurodegenerative disease
Andreasen et al. The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products
Ohta et al. Measurement of intact rat osteocalcin in osteoblast (ROS17/2.8) cells and in ovariectomized rats with a sandwich enzyme immunoassay
Liu et al. Immunochemical determination of LDH-1
JP3998245B2 (ja) 酸化アポリポタンパク質ａｉ及びそれを含有する酸化リポタンパク質の測定法及びキット
JP3499875B2 (ja) 解離性大動脈瘤を検出するための抗体試薬及びその用途
ZA200309593B (en) Method for kidney disease detection by protein profiling.
de Cos et al. Parent cyclosporine in whole blood by monoclonal fluorescence polarization immunoassay for Axsym and monoclonal enzyme-multiplied immunoassay for Cobas-Fara
JPH09318627A (ja) 腎不全またはバセドウ病における骨組織の代謝異常をスクリーニングする方法
JP2007279066A (ja) 酸化アポリポタンパク質ａｉ及びそれを含有する酸化リポタンパク質の測定法及びキット
JPH0833398B2 (ja) ヒト組織プラスミノーゲンアクチベーター・ヒトプラスミノーゲンアクチベーターインヒビター複合体の測定方法及び測定キット
HK1068653A (en) Method for kidney disease detection by protein profiling

Legal Events

Date Code Title Description
AS Assignment

Owner name: MONASH UNIVERSITY, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COMPER, WAYNE D.;REEL/FRAME:012185/0976

Effective date: 20010917

AS Assignment

Owner name: NORTHSHORE ASSET MANAGEMENT, LLC, ILLINOIS

Free format text: SECURITY AGREEMENT;ASSIGNOR:AUSAM BIOTECHNOLOGIES, INC.;REEL/FRAME:015074/0827

Effective date: 20031201

AS Assignment

Owner name: TRIDENT GROWTH FUND, LP, TEXAS

Free format text: SECURITY AGREEMENT;ASSIGNOR:AUSAM BIOTECHNOLOGIES, INC.;REEL/FRAME:016182/0255

Effective date: 20050421

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION